What is the official website of Sandoz México ?

The official website of Sandoz México is https://sandoz.com.mx.

What is Sandoz México's cybersecurity risk score?

Sandoz México has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Sandoz México experienced?

According to Rankiteo, Sandoz México currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Sandoz México been affected by any supply chain cyber incidents ?

According to Rankiteo, Sandoz México has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Sandoz México have SOC 2 Type 1 certification ?

According to Rankiteo, Sandoz México is not certified under SOC 2 Type 1.

Does Sandoz México have SOC 2 Type 2 certification ?

According to Rankiteo, Sandoz México does not hold a SOC 2 Type 2 certification.

Does Sandoz México comply with GDPR ?

According to Rankiteo, Sandoz México is not listed as GDPR compliant.

Does Sandoz México have PCI DSS certification ?

According to Rankiteo, Sandoz México does not currently maintain PCI DSS compliance.

Does Sandoz México comply with HIPAA ?

According to Rankiteo, Sandoz México is not compliant with HIPAA regulations.

Does Sandoz México have ISO 27001 certification ?

According to Rankiteo,Sandoz México is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Sandoz México operate in ?

Sandoz México operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Sandoz México have ?

Sandoz México employs approximately 170 people worldwide.

Does Sandoz México own any subsidiaries ?

Sandoz México presently has no subsidiaries across any sectors.

How many LinkedIn followers does Sandoz México have ?

Sandoz México's official LinkedIn profile has approximately 21,173 followers.

What is the NAICS classification code for Sandoz México ?

Sandoz México is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Sandoz México have a Crunchbase profile ?

No, Sandoz México does not have a profile on Crunchbase.

Does Sandoz México have a LinkedIn profile ?

Yes, Sandoz México maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/sandozmexico.

How many cybersecurity incidents has Sandoz México experienced ?

As of July 22, 2026, Rankiteo reports that Sandoz México has not experienced any cybersecurity incidents.

How many peer or competitor companies does Sandoz México have ?

Sandoz México has an estimated 5,710 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Sandoz México

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

Sandoz México Vendor Cyber Rating & Cyber Score

sandoz.com.mx

Add Your Compliance Badge

Somos líder mundial en medicamentos genéricos y biocomparables. Estamos presentes en más de 100 países y nuestros medicamentos atienden a unos 500 millones de personas cada año. Consulta nuestro aviso de privacidad en: https://www.sandoz.com.mx/aviso-de-privacidad.html

Sandoz México A.I CyberSecurity Scoring

Scoring History

Sandoz México

Sandoz México CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Sandoz México Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Sandoz México

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Sandoz México in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Sandoz México in 2026.

Incident Types Sandoz México vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Sandoz México in 2026.

Incident History - Sandoz México (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Sandoz México Subsidiaries

Sandoz México

Pharmaceutical Manufacturing

Website: https://sandoz.com.mx

Company Size: 5,001-10,000 employees

SandozPharmaceutical Manufacturing

Sandoz do BrasilFabricação de produtos farmoquímicos e farmacêuticos

Lek PharmaceuticalsPharmaceutical Manufacturing

Sandoz ItaliaPharmaceutical Manufacturing

Sandoz CanadaPharmaceutical Manufacturing

Sandoz Czech RepublicPharmaceutical Manufacturing

Sandoz EgyptPharmaceutical Manufacturing

Sandoz FrancePharmaceutical Manufacturing

Sandoz UK & IrelandPharmaceutical Manufacturing

Sandoz NederlandPharmaceutical Manufacturing

Sandoz IberiaPharmaceutical Manufacturing

Sandoz SrbijaPharmaceutical Manufacturing

Sandoz Australia & New ZealandPharmaceutical Manufacturing

Sandoz SverigePharmaceutical Manufacturing

Life at SandozArzneimittelherstellung

Sandoz PolskaPharmaceutical Manufacturing

Sandoz DanmarkPharmaceutical Manufacturing

Sandoz HungáriaPharmaceutical Manufacturing

Sandoz HrvatskaPharmaceutical Manufacturing

Sandoz India Pvt LtdPharmaceutical Manufacturing

Sandoz RomaniaPharmaceutical Manufacturing

Sandoz ÖsterreichPharmaceutical Manufacturing

Sandoz BelgiumPharmaceutical Manufacturing

Sandoz in DeutschlandPharmaceutical Manufacturing

Loading…

Sandoz México Similar Companies

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

Novartis

cb novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Loading…

NEWS

Sandoz México CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

July 21, 2021 07:00 AM

Generics, Biosimilar Leader to Expand Access, Reduce Costs

Q: How did Sandoz achieve its leading position in the generics sector and what strategies has the company implemented to maintain its...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-63261

SUMMARY

Uncontrolled Resource Consumption (CWE-400) in Kibana can lead to denial of service via Excessive Allocation (CAPEC-130). A low-privileged authenticated user can send a specially crafted request to a Kibana machine learning feature, causing the server to exhaust available memory and become unavailable to all users.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/kibana-8-19-19-9-3-8-9-4-4-security-update-esa-2026-72/388575

CVE-2026-63260

SUMMARY

Uncontrolled Resource Consumption (CWE-400) in Kibana can lead to denial of service via Excessive Allocation (CAPEC-130). An authenticated attacker with low-privilege access can trigger a denial of service condition in Kibana by sending a specially crafted, oversized request payload. Processing this user-supplied input requires resource-intensive memory allocation that can exhaust the available heap memory in the Kibana process, causing it to crash and become unavailable to all users.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/kibana-8-19-19-9-3-8-9-4-4-security-update-esa-2026-71/388574

CVE-2026-63259

SUMMARY

Authorization Bypass Through User-Controlled Key (CWE-639) in Kibana can lead to information disclosure via user-supplied identifiers that reference scheduled query result data from Kibana Spaces the requester is not authorized to access.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 4.3)

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N

Impact Score

1.4

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/kibana-9-4-4-security-update-esa-2026-70/388573

CVE-2026-63145

SUMMARY

Incorrect Authorization (CWE-863) in Kibana can lead to integrity compromise of Machine Learning audit and notification records via Accessing Functionality Not Properly Constrained by ACLs (CAPEC-1). A vulnerability exists in Kibana's Machine Learning functionality where a Machine Learning management endpoint performs an insufficient authorization check. The endpoint validates only a coarse privilege level but does not verify that the requesting user has access to the specific Machine Learning job or notification resources provided in the request. As a result, a low-privileged user with Machine Learning access in any Kibana space can manipulate Machine Learning audit and notification records for arbitrary jobs—including jobs in other spaces or belonging to other users—by leveraging Kibana's internally elevated credentials to write to restricted Machine Learning system indices that the user cannot access directly.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 4.3)

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:N

Impact Score

1.4

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/kibana-8-19-19-9-3-8-9-4-4-security-update-esa-2026-69/388572

CVE-2026-63144

SUMMARY

Uncontrolled Recursion (CWE-674) in Elasticsearch can lead to denial of service via a specially crafted search request submitted by a low-privileged authenticated user. A user with read-level index access can submit a request that triggers unbounded recursive processing within the Elasticsearch query evaluation component, causing a fatal error that terminates the affected node. In single-node deployments, this results in complete service outage; in multi-node clusters, it causes repeated node restarts and sustained availability degradation.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/elasticsearch-8-19-19-9-3-8-9-4-4-security-update-esa-2026-68/388571

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…